Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Synthesis of 2-oxoquinoline derivatives as dual pim and mTORC protein kinase inhibitors
Giri R. Gnawali ; Koichi Okumura ; Karolina Perez , et al. Med. Chem. Res.,2022,31(7):1154-1175. DOI: 10.1007/s00044-022-02904-z PubMed ID: 36389181
More
Abstract: Compound VBT-5445 was identified as an inhibitor to block the association of Pim and the protein Enhancer of Decapping 3 (EDC3), a Pim substrate, which normally functions to enhance the decapping of messenger RNA (mRNA). It was also shown to inhibit both the Pim and mTORC protein kinases. The activity of this compound class can be fine-tuned by structural modification. A series of VBT analogs were designed, synthesized, and evaluated. These compounds decrease the growth of multiple cancer types, including pancreas, prostate, breast, lung, and leukemia. Notably, 6-methyl (GRG-1-31, 6d), 4-chloro (GRG-1-34, 6e), 4-Bromo (GRG-1-35, 6f), and phenylthio substituted (GRG-1-104, 6n) derivatives are highly potent at inhibiting tumor growth. The ability of these compounds to block cancer growth in vitro is highly correlated with their activity as mTORC inhibitors. The toxicity of GRG 1–34 is low in mice treated with twice-daily gavage for 30 days and did not induce weight loss. Pharmacokinetics of a single oral dose demonstrated a peak concentration at 0.5?h after gavage. In summary, further development of this compound class has the potential to inhibit important signaling pathways and impact cancer treatment.
Keywords: Quinoline derivatives ; Pim kinase ; Antitumor activity ; mTORC
Purchased from AmBeed: 180748-30-5 ; 4837-01-8 ; 589-10-6 ; 6627-60-7 ; 31106-82-8 ; 1260903-05-6 ; 865156-50-9 ; 188637-63-0 ; 103-67-3 ; 3731-51-9 ; 164341-39-3 ; 67938-76-5 ; 22921-76-2 ; 1241725-81-4 ; 872577-05-4 ; 131052-62-5 ; 184637-50-1 ...More
CAS No. : | 180748-30-5 | MDL No. : | MFCD07374904 |
Formula : | C6H7ClN2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FZCYDUZIHRNWSQ-UHFFFAOYSA-N |
M.W : | 142.59 | Pubchem ID : | 22727148 |
Synonyms : |
|
Signal Word: | Warning | Class: | |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | |
Hazard Statements: | H317-H319 | Packing Group: | |
GHS Pictogram: |
[ 871826-13-0 ]
(5-Chloropyridin-2-yl)methanamine hydrochloride
Similarity: 0.82
[ 67938-76-5 ]
(5-Chloropyridin-2-yl)methanamine
Similarity: 0.82
[ 871826-13-0 ]
(5-Chloropyridin-2-yl)methanamine hydrochloride
Similarity: 0.82
[ 67938-76-5 ]
(5-Chloropyridin-2-yl)methanamine
Similarity: 0.82
[ 500305-98-6 ]
(3-Chloropyridin-2-yl)methanamine
Similarity: 0.78
[ 871826-13-0 ]
(5-Chloropyridin-2-yl)methanamine hydrochloride
Similarity: 0.82
[ 67938-76-5 ]
(5-Chloropyridin-2-yl)methanamine
Similarity: 0.82